<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296825</url>
  </required_header>
  <id_info>
    <org_study_id>FDLT2DM-01</org_study_id>
    <nct_id>NCT04296825</nct_id>
  </id_info>
  <brief_title>Effect of Camel Milk With Probiotic on Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Camel Milk Containing Bifidobacterium Animalis A6 on Chinese People With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Agricultural University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chinese Medicine Hospital-Pinggu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Agricultural University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of dietary supplement with Camel Milk
      containing Bifidobacterium animalis A6 on the plasma glucose and other related cytokines in
      patients with type 2 diabetes mellitus. 45 patients with type 2 diabetes mellitus were
      recruited, and a Double Blind Randomized Parallel Controlled Trial was performed. The fasting
      glycaemia, 2 hour postprandial glycaemia, insulin, uric acid and serum lipid (total
      cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density
      lipoprotein cholesterol ) were measured as Primary Outcome. The Fecal microbiome, fecal
      metabolites, gut hormones (amylin, ghrelin, glucagon-like peptide 1, pancreatic polypeptide),
      inflammation cytokines (TNF-α, IL-6, MCP-1), myokines (FGF-21, irisin, osteocrin/musclin,
      osteonectin) and adipokines (adiponectin, resistin, lipocalin-2, adipsin) and body
      composition analysis were also assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">July 9, 2018</completion_date>
  <primary_completion_date type="Actual">June 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fasting blood glucose and 2 hour postprandial blood glucose in millimole per liter and insulin in μU/mL</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in lipid profiles (total cholesterol, total triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in millimole per liter)</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammation cytokines ( TNF-α, IL-6 and MCP-1 in petagram per milliliter)</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal microbiome</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal metabolites were identified by GC-MS after extracted with methanol, then oximated with methoxyamine hydrochloride and trimethylsilylated with BSTFA. The concentration was calculated as the area of the peak and normalized to the internal standard.</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body composition (bodyweight in kilograms, height in meters and visceral fat content in square centimeters and body fat in % were measured using the bioelectrical impedance method (BAS-H, SEEHIGHER, Beijing China). )</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in myokines (FGF21, irisin, osteocrin, and osteonectin in petagram per milliliter) and adipokines (adiponectin and adipsin in microgram per milliliter and resistin and lipocalin-2 in petagram per milliliter)</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut hormones (amylin, ghrelin, GLP-1, PP and PYY in petagram per milliliter)</measure>
    <time_frame>4 weeks</time_frame>
    <description>follow up the patients at week 0, 4</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received cow milk for 4 consecutive weeks (two times per day, 10 gram each time).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received camel milk with Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received camel milk for 4 consecutive weeks (two times per day, 10 gram each time).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Bifidobacterium animalis A6 at a dose of 2×1010 viable cells for 4 consecutive weeks (two times per day, 10 gram each time).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Camel milk containing Bifidobacterium animalis A6</intervention_name>
    <description>Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.</description>
    <arm_group_label>CA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Camel milk</intervention_name>
    <description>Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium animalis A6</intervention_name>
    <description>Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cow milk</intervention_name>
    <description>Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 35~68 years old

          -  Patients who diagnosed as type 2 diabetes

          -  Agree to take the products to be studied during the study period, and no longer take
             other fermented dairy products (live lactic acid bacteria drinks, cheese, yogurt,
             probiotic products, etc.) and antibiotic

          -  Agree to sign the informed consent form

        Exclusion Criteria:

          -  Taking antibiotics or antifungal drugs within 7 days before the study

          -  Have serious allergic reaction to skim milk powder or milk

          -  Researcher are not sure whether the subjects are willing or able to complete the study

          -  Subject had other serious diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Chinese Medicine Hospital Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Auer HE, Doty P. The synthesis, structure, and optical properties of some copolypeptides containing nonpolar amino acid residues. Biochemistry. 1966 May;5(5):1708-15.</citation>
    <PMID>5961288</PMID>
  </reference>
  <results_reference>
    <citation>Agrawal RP, Budania S, Sharma P, Gupta R, Kochar DK, Panwar RB, Sahani MS. Zero prevalence of diabetes in camel milk consuming Raica community of north-west Rajasthan, India. Diabetes Res Clin Pract. 2007 May;76(2):290-6. Epub 2006 Nov 13.</citation>
    <PMID>17098321</PMID>
  </results_reference>
  <results_reference>
    <citation>Saigusa M, Mizuno A, Morimoto K, Nakamura K. [Acute postoperative renal failure due to extracorporeal circulation--with reference to the evaluation of fatal cases]. Kyobu Geka. 1967 Sep;20(9):594-9. Japanese.</citation>
    <PMID>5626114</PMID>
  </results_reference>
  <results_reference>
    <citation>Casini F, Sbarigia V, Schiavone C. [Identification of Cannabis indica in the residues of incomplete combustion of the drug]. Boll Chim Farm. 1969 May;108(5):330-6. Italian.</citation>
    <PMID>5806827</PMID>
  </results_reference>
  <results_reference>
    <citation>Baumgarten A, Melrose GJ, Vagg WJ. Continuous recording of dermal exudative reactions. Dermatologica. 1970;140(4):219-24.</citation>
    <PMID>5425915</PMID>
  </results_reference>
  <results_reference>
    <citation>Burdon JF. [Medicine in Great Britain]. Concours Med. 1965 Oct 9;87(41):5799-803. French.</citation>
    <PMID>5857053</PMID>
  </results_reference>
  <results_reference>
    <citation>Lavin MF, Seymour GJ. Reduced levels of fibronectin in ataxia-telangiectasia lymphoblastoid cells. Int J Cancer. 1984 Mar 15;33(3):359-63.</citation>
    <PMID>6365801</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Agricultural University</investigator_affiliation>
    <investigator_full_name>Fazheng Ren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Camel Milk</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Gut Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

